1228570-47-5

Basic information

• Product Name: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID
• Synonyms: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID;Boc-(R)-2-amino-2-(4-bromophenyl)acetic acid;(R)-2-(4-Bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid;N-Boc-R-4-Bromophenylglycine
• CAS NO: 1228570-47-5
• Molecular Formula: C13H16BrNO4
• Molecular Weight: 330.17444
• EINECS: -0
• Mol File: 1228570-47-5.mol

Chemical Properties

• Boiling Point: 465.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.443±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.38±0.10(Predicted)
• CAS DataBase Reference: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(1228570-47-5)
• EPA Substance Registry System: (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID(1228570-47-5)

Safety Data

• Hazardous Substances Data: 1228570-47-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Drug Development:
(2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure and functional groups enable the development of new drug candidates with improved therapeutic properties and reduced side effects.
Used in Organic Synthesis:
In the field of organic synthesis, (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID serves as a versatile building block for the creation of complex organic molecules. Its reactivity and functional groups allow for various chemical transformations, leading to the formation of a wide range of compounds with diverse applications.
Used in Medicinal Chemistry Research:
(2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID is employed as a research tool in medicinal chemistry to study the structure-activity relationships of biologically active compounds. Its unique stereochemistry and functional groups provide insights into the molecular interactions between drug candidates and their target proteins, aiding in the design of more effective and selective therapeutic agents.
Used in Chiral Compound Synthesis:
As a chiral compound, (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID is utilized in the synthesis of enantiomerically pure compounds. Its 2R stereochemistry can be exploited to produce chiral molecules with specific biological activities, which is crucial in the development of drugs with improved efficacy and reduced side effects.
Used in Biochemical and Analytical Applications:
(2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-2-(4-BROMOPHENYL)ACETIC ACID can be employed as a chiral selector in chromatographic techniques, such as high-performance liquid chromatography (HPLC) and capillary electrophoresis (CE), for the separation and analysis of enantiomers. Its unique stereochemistry and functional groups enable the efficient resolution of chiral compounds, providing valuable information for drug development and quality control processes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 
• 848188-26-1 (S)-Amino-(4-bromo-phenyl)-acetic acid 
• 71079-03-3 (R)-4-bromophenylglycine 

Downstream Products

• 917925-68-9 [(4-bromo-phenyl)-(5-phenyl-1H-imidazol-2-yl)-methyl]-carbamic acid tert-butyl ester 
• 369403-44-1 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 

Relevant articles and documents

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines

The serine protease, PACE4, is a proprotein convertase that plays a substantial role in malignancy of prostate cancer. Our initial selective PACE4 inhibitor (Ac-LLLLRVKR-NH2) has evolved to the current lead compound C23 (Ac-dLeu-LLLRVK-Amba), w

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS

Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

Substituted hydantoins

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.